Bromfenac (Duract)-associated hepatic failure requiring liver transplantation.
Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.
Hunter
E B
EB
Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232-2279, USA.
Johnston
P E
PE
Tanner
G
G
Pinson
C W
CW
Awad
J A
JA
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001577:Benzophenones / Q000008:administration & dosage / Q000009:adverse effects*; D001969:Bromobenzenes / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced* / Q000601:surgery; D008111:Liver Function Tests; D016031:Liver Transplantation; D008134:Long-Term Care; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; C053083:bromfenac